Skip to content

ANI Pharmaceuticals ANIP Prepaid expenses

Prepaid expenses at other companies

Viatris logo
ViatrisVTRS
XER
Xeris Biopharma Holdings, Inc.XERS
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD

Other financials

Income statement

See full
Revenue$237.5M+20.5%
Gross profit$143.9M+16.0%
Operating income$38.9M+48.5%
Net income$29.5M+88.1%
EPS (diluted)$1.28+85.5%

Balance sheet

See full
Cash & equivalents$311.2M+108%
Total debt$305.3M-3.5%
Total equity$562.3M+34.3%
Total assets$1.4B+10.0%

Cash flow

See full
Operating cash flow$58.4M+66.8%
CapEx$6.1M+146%
Free cash flow$52.3M+60.8%

Valuation

See full
Market cap$1.88B+18.3%
Enterprise value$1.87B+5.8%
P/E20.4×
P/S-0.3×

Profitability

See full
Gross margin60.8%+1.5pp
Operating margin13.4%
Net margin10%+8.1pp
FCF margin20.7%+10.8pp

Returns & leverage

See full
Return on equity18.8%+15.6pp
Debt / equity0.5×-0.2×
Current ratio3.1×+0.5×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseCurrent.

The official record: ANI Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about ANI Pharmaceuticals's prepaid expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ANI Pharmaceuticals's prepaid expenses?
ANI Pharmaceuticals (ANIP) reported prepaid expenses of $22.09M in Q1 2026.
How has ANI Pharmaceuticals's prepaid expenses changed year-over-year?
ANI Pharmaceuticals's prepaid expenses decreased by 5.3% year-over-year, from $23.33M to $22.09M.
What is the long-term trend for ANI Pharmaceuticals's prepaid expenses?
Over 5 years (2020 to 2025), ANI Pharmaceuticals's prepaid expenses has grown at a 42.3% compound annual growth rate (CAGR), from $5.86M to $34.22M.